

Ioannis Parodis

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4729699/ioannis-parodis-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61

papers

821

citations

16

h-index

27

g-index

89

ext. papers

1,454

ext. citations

5.5

avg, IF

4.75

L-index

#	Paper	IF	Citations
61	Patient-Reported Outcomes in Systemic Lupus Erythematosus. Can Lupus Patients Take the Driver's Seat in Their Disease Monitoring?. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	1
60	The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses.. <i>Journal of Clinical Investigation</i> , 2022 , 132,	15.9	2
59	Treat-to-Target in Lupus Nephritis. What is the Role of the Repeat Kidney Biopsy?. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2022 , 70, 8	4	0
58	Vaccine hesitancy in patients with autoimmune diseases: Data from the coronavirus disease-2019 vaccination in autoimmune diseases study. <i>Indian Journal of Rheumatology</i> , 2022 ,	0.5	1
57	Patient-reported outcomes with anifrolumab in patients with systemic lupus erythematosus. <i>Lancet Rheumatology, The</i> , 2022 , 4, e157-e159	14.2	
56	Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Analysis of Three Phase III Clinical Trials of Belimumab.. <i>Frontiers in Immunology</i> , 2022 , 13, 796508	8.4	1
55	Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus.. <i>Frontiers in Medicine</i> , 2022 , 9, 852162	4.9	0
54	How to use the Lupus Low Disease Activity State (LLDAS) in clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e119	2.4	2
53	COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. <i>Rheumatology International</i> , 2021 , 1	3.6	7
52	Differentiating between UCTD and early-stage SLE: from definitions to clinical approach. <i>Nature Reviews Rheumatology</i> , 2021 ,	8.1	4
51	De novo lupus nephritis during treatment with belimumab. <i>Rheumatology</i> , 2021 , 60, 4348-4354	3.9	8
50	Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , 2021 , 8, 651249	4.9	4
49	POS0101 ADVERSE HEALTH-RELATED QUALITY OF LIFE OUTCOME DESPITE ADEQUATE CLINICAL RESPONSE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 260.2-261	2.4	
48	POS0779 MYOCARDIAL INFARCTIONS, SUBTYPES, LOCATIONS AND CORONARY ATHEROSCLEROSIS IN SLE - A COMPARATIVE STUDY WITH MATCHED CONTROLS. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 643.1-643	2.4	
47	BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors. <i>Scientific Reports</i> , 2021 , 11, 11632	4.9	0
46	Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case-control study. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	1
45	Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus. <i>Rheumatology</i> , 2021 , 60, 1260-1272	3.9	3

44	Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE. <i>Rheumatology</i> , 2021 , 60, 4205-4217	3.9	1
43	EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus. <i>Rheumatology</i> , 2021 , 60, 4703-4716	3.9	2
42	Fatigue in Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Comparison of Mechanisms, Measures and Management. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	7
41	From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift?. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	3
40	Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis. <i>Rheumatology</i> , 2020 , 59, 3424-3434	3.9	13
39	Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	11
38	Use of Antimalarial Agents is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
37	2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 713-723	2.4	173
36	B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice. <i>Frontiers in Medicine</i> , 2020 , 7, 316	4.9	21
35	Prediction of prognosis and renal outcome in lupus nephritis. <i>Lupus Science and Medicine</i> , 2020 , 7, e000348	3.9	20
34	Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention. <i>Current Vascular Pharmacology</i> , 2020 , 18, 549-565	3.3	19
33	OP0163 2019 UPDATE OF THE JOINT EUROPEAN LEAGUE AGAINST RHEUMATISM AND EUROPEAN RENAL ASSOCIATION/EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION (EULAR/ERA-EDTA) RECOMMENDATIONS FOR THE MANAGEMENT OF LUPUS NEPHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 668-669	2.4	0
32	FRI0168 ASSOCIATION OF OVERWEIGHT/OBESITY WITH IMPAIRED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 668-669	2.4	1
31	THU0248 GLOMERULAR AND TUBULOINTERSTITIAL LESIONS IN PER-PROTOCOL REPEAT BUT NOT BASELINE KIDNEY BIOPSY PORTEND RELAPSE AND LONG-TERM RENAL FUNCTION IMPAIRMENT, RESPECTIVELY, IN INCIDENT CASES OF PROLIFERATIVE LUPUS NEPHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 668-669	2.4	
30	ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus. <i>Rheumatology</i> , 2020 , 59, 2237-2249	3.9	15
29	P137 De novo lupus nephritis during belimumab treatment 2020 ,		1
28	Lupus nephritis. <i>Nature Reviews Disease Primers</i> , 2020 , 6, 7	51.1	127
27	Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus. <i>Rheumatology</i> , 2019 , 58, 2170-2176	3.9	18

26	G-CSF-induced aortitis: Two cases and review of the literature. <i>Autoimmunity Reviews</i> , 2019 , 18, 615-620	13.6	23
25	Serum Axl predicts histology-based response to induction therapy and long-term renal outcome in lupus nephritis. <i>PLoS ONE</i> , 2019 , 14, e0212068	3.7	5
24	The Impact of Belimumab and Rituximab on Health-Related Quality of Life in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019 , 71, 811-821	4.7	17
23	Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2019 , 18, 102372	13.6	10
22	Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials. <i>Lancet Rheumatology</i> , 2019 , 1, e163-e173	14.2	9
21	Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2019 , 21, 259	5.7	7
20	Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 157-168	5.4	14
19	Established organ damage reduces belimumab efficacy in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1006-1007	2.4	6
18	B cell alterations during BAFF inhibition with belimumab in SLE. <i>EBioMedicine</i> , 2019 , 40, 517-527	8.8	47
17	Increasing Reasoning Awareness: Video Analysis of Students' Two-Party Virtual Patient Interactions. <i>JMIR Medical Education</i> , 2018 , 4, e4	5	3
16	Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL. <i>Lupus</i> , 2018 , 27, 1470-1478	2.6	16
15	Smoking reduces the efficacy of belimumab in mucocutaneous lupus. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 911-920	5.4	11
14	Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017 , 16, 343-351	13.6	52
13	Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis. <i>Scandinavian Journal of Rheumatology</i> , 2017 , 46, 263-272	1.9	9
12	FRI0310 Serum Insulin-like Growth Factor-Binding Protein 2 (IGFBP2) as A Biomarker of Clinical and Histopathological Treatment Response in Lupus Nephritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 547.2-547	2.4	
11	Antiphospholipid Antibodies in Lupus Nephritis. <i>PLoS ONE</i> , 2016 , 11, e0158076	3.7	19
10	AB0458 Serum Ferritin as A Biomarker of Clinical and Histopathological Response To Treatment in Lupus Nephritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1063.1-1063	2.4	
9	Interferon (IFN)- β is a potential mediator in lupus nephritis. <i>Lupus Science and Medicine</i> , 2016 , 3, e000170	4.6	36

8	Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy. <i>Lupus Science and Medicine</i> , 2015 , 2, e000061	4.6	22
7	SAT0401 Antiphospholipid Antibodies in Lupus Nephritis and Their Role in Long-Term Outcome. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 804.2-804	2.4	
6	THU0530 Blys and APRIL in Lupus Nephritis: Correlations with Serology - Blys as A Non-Invasive Predictor of Response. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 366.3-366	2.4	
5	AB0487 Decreased SLE Disease Activity and Corticosteroid Usage and NO Renal Flares during Belimumab Treatment. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 968.2-968	2.4	1
4	THU0520 Interferon (IFN)-Lambda1/3, but not IFN-Alpha, is A Marker of Poor Response to Treatment in Lupus Nephritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 363.1-363	2.4	
3	Biologics in SLE: towards new approaches. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013 , 27, 341-9	5.3	21
2	Belimumab for systemic lupus erythematosus: a practice-based view. <i>Lupus</i> , 2013 , 22, 372-80	2.6	16
1	A5.12 Disappearance and Reappearance of IgG, IgA and IgM Autoantibody Isotypes and Immune Complexes in Rituximab-Treated SLE Patients. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A34.2-A34	2.4	